Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 73
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT00648102 | Phase I Study of CDX-1307, hCG-B Vaccine, for Patients With Incurable, Locally Advanced or Metastatic Breast, Colorectal, Pancreatic, Bladder or Ovarian Cancer | ||
| NCT03068650 | Expanded Access (Compassionate Use) Treatment Protocol Rindopepimut | ||
| NCT05349890 | Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T) | ||
| NCT02284971 | Pilot Study of SBRT and CDX-1127 in Prostate Cancer | ||
| NCT03617328 | Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma | ||
| NCT01791686 | Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease | ||
| NCT02270372 | Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer | ||
| NCT03254927 | A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma | ||
| NCT03358719 | DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia | ||
| NCT03835533 | Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations | ||
| NCT05405660 | A Study of CDX-0159 in Patients With Chronic Inducible Urticaria | ||
| NCT01460134 | A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers | ||
| NCT00412828 | A Phase I/II Study of CR011-vcMMAE in Subjects With Unresectable Stage III or Stage IV Melanoma | ||
| NCT05788484 | A Study of CDX-585 in Patients With Advanced Malignancies | ||
| NCT03789097 | Vaccination With Flt3L, Radiation, and Poly-ICLC | ||
| NCT04548869 | A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of CDX-0159 in Patients With Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic Urticaria | ||
| NCT01156753 | A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer | ||
| NCT00709462 | A Study of CDX-1307, in Patients With Incurable Breast, Colorectal, Pancreatic, Ovarian or Bladder Cancer (CDX 1307-01) | ||
| NCT02924038 | A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG) | ||
| NCT05774184 | A Study of CDX-0159 in Patients With Eosinophilic Esophagitis | ||
| NCT01976585 | In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy | ||
| NCT05484011 | A Maintenance Therapy Study of Odetiglucan With CDX-1140 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma | ||
| NCT03473691 | Pilot Study of Glembatumumab Vedotin Following Doxorubicin and Cytoxan as Neo-adjuvant Therapy in Gp-NMB-expressing High Risk Triple Negative Breast Cancer | ||
| NCT03580382 | Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma | ||
| NCT02200380 | A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs | ||
| NCT02543645 | A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer | ||
| NCT01480479 | Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma | ||
| NCT01465139 | A Study to Evaluate CDX-301 (rhuFlt3L) in Healthy Volunteers | ||
| NCT02386111 | A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma | ||
| NCT06445023 | A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria | ||
| NCT04536077 | Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients | ||
| NCT01997333 | Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer | ||
| NCT04146129 | A Phase 1 Study of CDX-0159 | ||
| NCT05368285 | A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria | ||
| NCT06455202 | A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU) | ||
| NCT02837991 | A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma | ||
| NCT04440943 | A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies | ||
| NCT02302339 | A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma | ||
| NCT03329950 | A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies | ||
| NCT06650761 | A Phase I Study of CDX-622 | ||
| NCT04491084 | FLT3 Ligand, CD40 Agonist Antibody, and Stereotactic Radiotherapy | ||
| NCT02713828 | Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the Lung | ||
| NCT03067935 | Individual Patient Expanded Access-Glembatumumab Vedotin | ||
| NCT03688178 | DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab | ||
| NCT04538794 | A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria | ||
| NCT02839265 | FLT3 Ligand Immunotherapy and Stereotactic Radiotherapy for Advanced Non-small Cell Lung Cancer | ||
| NCT05231122 | Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer | ||
| NCT05029999 | CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer | ||
| NCT02413827 | A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma | ||
| NCT04364230 | Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma) |
